** Brokerage Leerink Partners raises PT on drugmaker Gilead Sciences GILD.O to $114 from $105
** Brokerage says it does not anticipate any "major top- or bottom-line surprises" in GILD's earnings, ahead of its Q2 results likely to be reported in early August
** Maintains "outperform" rating
** The new price target represents a 3.97% upside to the stock's last close
** Aside from earnings, brokerage says "the central focus will be on two recent HIV PrEP and treatment pipeline developments"
** Brokerage says GILD's recently approved twice-yearly injectable HIV PrEP, Yeztugo, can quickly and widely become available, considering its lower price compared to its once-daily PrEP drug, Descovy, and its efficacy even though unclear guidelines after U.S. top court ruling on preventative coverage and CMS
** Twenty of 30 brokerages rate the stock "buy" or higher, 10 "hold"; their median PT is $118.50 - data compiled by LSEG
** Up to last close, stock up 18.7% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.